1. Opening Hook
January 2026 started with CORONA Remedies reminding the market why it didn’t come to the party just to list and leave. While most pharma players are busy blaming pricing pressure, CORONA calmly walked in and said, “We grew faster anyway.”
The concall felt like a victory lap disguised as an analyst presentation—rank jumps, margin expansion, chronic dominance, and brands behaving like obedient overachievers. Management wasn’t shouting; the numbers were doing that job.
But beneath the growth swagger lies the real test: can CORONA keep outpacing IPM without tripping on scale, working capital, or acquisition indigestion?
Stick around. The brands get stronger, margins get fatter, and confidence stays uncomfortably high.
2. At a Glance
- Revenue up 15.1% (Q2): IPM grew, CORONA sprinted past.
- H1 revenue up 17.0%: Consistency—pharma’s rarest vitamin.
- EBITDA up 17.4% (Q2): Costs behaved, management smiled.
- H1 PAT up 35.1%: Profits didn’t just grow, they showed off.
- EBITDA margin +170 bps (H1): Operating leverage finally clocked in.
3. Management’s Key Commentary
“CORONA has grown at 1.82x compared to IPM.”
(Translation: We don’t benchmark ourselves against mediocrity.) 😏
“Chronic portfolio contributes over 70% of revenues.”
(Translation: Predictability > adrenaline-fueled acute sales.)
“We jumped 8 ranks in 3 years.”
(Translation: Sales teams didn’t take weekends off.)
“Brand building remains central to our strategy.”
(Translation: Fewer brands, more muscle.)
“Acquisitions are disciplined and value-accretive.”
(Translation: No random shopping sprees—mostly.)
“We see sustained margin expansion ahead.”
(Translation: Assuming doctors, distributors, and regulators cooperate.) 😌
4. Numbers Decoded
Metric | Q2 FY26 | Q2 FY25 | H1 FY26 | H1 FY25
--------------------------|---------|---------|---------|---------
Revenue (₹ Cr) | 361.1 | 313.9 | 707.7 |
